AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_02_05_2025_05_53_40_418159.jpg)
Highlights
- Preliminary Q1 FY2025 revenue reached $1.02 billion, a 0.9% YoY increase.
- Diagnostics division grew 9.0% organically, excluding COVID-19 contributions.
- Skeletal Health division saw a sharp decline of 37.8%.
Hologic Inc. (NASDAQ:HOLX) has released preliminary financial results for the first quarter of fiscal year 2025, revealing a slight year-over-year revenue growth and a mixed performance across its key divisions. The company reported revenue of $1,021.8 million, a modest 0.9% increase compared to the same period last year, or 1.0% when adjusting for constant currency fluctuations. Despite facing currency headwinds that impacted revenue by approximately $9 million, Hologic expects its GAAP and non-GAAP earnings per share to be near the high end of its previously set guidance ranges.
Division Performance Overview:
- Diagnostics Division: The Diagnostics division emerged as a key performer, posting a 5.1% revenue growth, reaching $470.6 million. Notably, organic growth, excluding the impact of COVID-19 testing, surged by 9.0%. This increase signals a healthy demand for Hologic’s diagnostic products beyond the pandemic, with key offerings likely contributing to strong results.
- Breast Health Division: In contrast, the Breast Health division experienced a decline of 2.3%, bringing in $369.1 million in revenue. The downturn in this sector reflects ongoing challenges in the healthcare industry, with lower demand for certain diagnostic and imaging services compared to previous periods.
- GYN Surgical Division: The GYN Surgical division reported a solid 2.5% increase in revenue, totaling $166.3 million. This growth is indicative of sustained demand for women’s health solutions, particularly in minimally invasive surgical technologies.
- Skeletal Health Division: One of the biggest disappointments came from the Skeletal Health division, which saw a significant 37.8% decline in revenue, dropping to $15.8 million. The sharp decrease highlights challenges in this segment, which could be due to a variety of factors including reduced demand or competitive pressures.
Outlook: Despite the mixed results, Hologic remains cautiously optimistic about the remainder of fiscal year 2025. The company plans to provide a more detailed financial update, along with an updated guidance for Q2 and the full fiscal year, during its earnings call on February 5, 2025. This guidance will be keenly awaited by investors and analysts, as it could provide further insight into the company’s ability to navigate headwinds in its weaker divisions.
